Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Apr;21(4):401–408. doi: 10.1111/j.1365-2125.1986.tb05214.x

Racial differences in drug responses--a comparative study of trimazosin and alpha 1-adrenoceptor responses in normotensive Caucasians and West Africans.

J Vincent, H L Elliott, P A Meredith, J L Reid
PMCID: PMC1400935  PMID: 3011048

Abstract

The possible racial differences in alpha 1-adrenoceptor responsiveness and the blood pressure and heart rate responses following alpha 1-adrenoceptor antagonism with trimazosin have been investigated in matched groups of six Caucasians and six Nigerians. There were no significant differences between the racial groups in the blood pressure and heart rate responses to oral (200 mg) and intravenous (100 mg) trimazosin. alpha 1-adrenoceptor responsiveness was similar in both groups after placebo and following both active treatments. There were only minor pharmacokinetic differences with the Caucasians having a larger volume of distribution, and a longer terminal elimination half-life for the metabolite, 1-hydroxy-trimazosin. These results suggest a similarity in peripheral vascular alpha 1-adrenoceptor mechanisms and show no major significant racial differences in the pharmacokinetics and pharmacodynamics of trimazosin.

Full text

PDF
401

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvares A. P., Anderson K. E., Conney A. H., Kappas A. Interactions between nutritional factors and drug biotransformations in man. Proc Natl Acad Sci U S A. 1976 Jul;73(7):2501–2504. doi: 10.1073/pnas.73.7.2501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anderson K. E., Conney A. H., Kappas A. Nutrition and oxidative drug metabolism in man: relative influence of dietary lipids, carbohydrate, and protein. Clin Pharmacol Ther. 1979 Oct;26(4):493–501. doi: 10.1002/cpt1979264493. [DOI] [PubMed] [Google Scholar]
  3. Aronow W. S., Greenfield R. S., Alimadadian H., Danahy D. T. Effect of the vasodilator trimazosin versus placebo on exercise performance in chronic left ventricular failure. Am J Cardiol. 1977 Nov;40(5):789–793. doi: 10.1016/0002-9149(77)90198-9. [DOI] [PubMed] [Google Scholar]
  4. Aronow W. S., Tobis J., Hughes D., Siegel J., Easthope J. Comparison of trimazosin and methyldopa in hypertension. Clin Pharmacol Ther. 1977 Oct;22(4):425–429. doi: 10.1002/cpt1977224425. [DOI] [PubMed] [Google Scholar]
  5. Awan N. A., Hermanovich J., Whitcomb C., Skinner P., Mason D. T. Cardiocirculatory effects of afterload reduction with oral trimazosin in severe chronic congestive heart failure. Am J Cardiol. 1979 Jul;44(1):126–131. doi: 10.1016/0002-9149(79)90261-3. [DOI] [PubMed] [Google Scholar]
  6. De Gula D., Mendlowitz M., Russo C., Vlachakis N. D., Antram S. The effect of trimazosin in essential hypertension. Curr Ther Res Clin Exp. 1973 Jul;15(7):339–348. [PubMed] [Google Scholar]
  7. Falase A. O., Salako L. A., Aminu J. M. Lack of effect of low doses of prazosin in hypertensive Nigerians. Curr Ther Res Clin Exp. 1976 Jun;19(6):603–611. [PubMed] [Google Scholar]
  8. Franciosa J. A., Cohn J. N. Hemodynamic effects of trimazosin in patients with left ventricular failure. Clin Pharmacol Ther. 1978 Jan;23(1):11–18. doi: 10.1002/cpt197823111. [DOI] [PubMed] [Google Scholar]
  9. Fraser H. S., Mucklow J. C., Bulpitt C. J., Khan C., Mould G., Dollery C. T. Environmental effects on antipyrine half-life in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):799–808. doi: 10.1002/cpt1977225part2799. [DOI] [PubMed] [Google Scholar]
  10. Hietanen E. Modification of hepatic drug metabolizing enzyme activities and their induction by dietary protein. Gen Pharmacol. 1980;11(5):443–450. doi: 10.1016/0306-3623(80)90030-0. [DOI] [PubMed] [Google Scholar]
  11. Houston J. B. Drug metabolite kinetics. Pharmacol Ther. 1981;15(3):521–552. doi: 10.1016/0163-7258(81)90056-5. [DOI] [PubMed] [Google Scholar]
  12. Hughes M. A., Meredith P. A., Elliott H. L. The determination of trimazosin and its metabolite CP23445 in whole blood by high performance liquid chromatography using fluorescence detection. J Pharmacol Methods. 1984 Aug;12(1):29–34. doi: 10.1016/0160-5402(84)90003-2. [DOI] [PubMed] [Google Scholar]
  13. Humphreys G. S., Delvin D. G. Ineffectiveness of propranolol in hypertensive Jamaicans. Br Med J. 1968 Jun 8;2(5605):601–603. doi: 10.1136/bmj.2.5605.601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982 Sep-Oct;7(5):373–400. doi: 10.2165/00003088-198207050-00001. [DOI] [PubMed] [Google Scholar]
  15. Kappas A., Alvares A. P., Anderson K. E., Pantuck E. J., Pantuck C. B., Chang R., Conney A. H. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin Pharmacol Ther. 1978 Apr;23(4):445–450. doi: 10.1002/cpt1978234445. [DOI] [PubMed] [Google Scholar]
  16. Kappas A., Anderson K. E., Conney A. H., Alvares A. P. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther. 1976 Dec;20(6):643–653. doi: 10.1002/cpt1976206643. [DOI] [PubMed] [Google Scholar]
  17. Mbanefo C., Bababunmi E. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica. 1980 Nov;10(11):811–818. doi: 10.3109/00498258009033811. [DOI] [PubMed] [Google Scholar]
  18. Meredith P. A., Kelman A. W., Elliott H. L., Reid J. L. Pharmacokinetic and pharmacodynamic modelling of trimazosin and its major metabolite. J Pharmacokinet Biopharm. 1983 Aug;11(4):323–335. doi: 10.1007/BF01058953. [DOI] [PubMed] [Google Scholar]
  19. Reid J. L., Meredith P. A., Elliott H. L. Pharmacokinetics and pharmacodynamics of trimazosin in man. Am Heart J. 1983 Nov;106(5 Pt 2):1222–1228. doi: 10.1016/0002-8703(83)90179-5. [DOI] [PubMed] [Google Scholar]
  20. Salako L. A., Falase A. O., Aderounmu A. F. Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients. Curr Med Res Opin. 1979;6(5):358–363. doi: 10.1185/03007997909109451. [DOI] [PubMed] [Google Scholar]
  21. Scott J. G. THE EYE OF THE WEST AFRICAN NEGRO. Br J Ophthalmol. 1945 Jan;29(1):12–19. doi: 10.1136/bjo.29.1.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Seedat Y. K., Reddy J. Propranolol in the South African non-white hypertensive patient. S Afr Med J. 1971 Mar 13;45(11):284–285. [PubMed] [Google Scholar]
  23. Singleton W., Saxton C. A., Hernandez J., Prichard B. N. Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man. J Cardiovasc Pharmacol. 1982;4 (Suppl 1):S145–S151. doi: 10.1097/00005344-198200041-00029. [DOI] [PubMed] [Google Scholar]
  24. Spector R., Choudhury A. K., Chiang C. K., Goldberg M. J., Ghoneim M. M. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther. 1980 Aug;28(2):229–234. doi: 10.1038/clpt.1980.155. [DOI] [PubMed] [Google Scholar]
  25. Sumner D. J., Elliott H. L., Reid J. L. Analysis of the pressor dose response. Clin Pharmacol Ther. 1982 Oct;32(4):450–458. doi: 10.1038/clpt.1982.188. [DOI] [PubMed] [Google Scholar]
  26. Vlachakis N. D., Mendlowitz M., De Guzman de Guzman D. Treatment of essential hypertension with trimazosin, a new vasodilator agent. Curr Ther Res Clin Exp. 1975 Jun;17(6):564–569. [PubMed] [Google Scholar]
  27. Weber K. T., Kinasewitz G. T., West J. S., Janicki J. S., Reichek N., Fishman A. P. Long-term vasodilator therapy with trimazosin in chronic cardiac failure. N Engl J Med. 1980 Jul 31;303(5):242–250. doi: 10.1056/NEJM198007313030502. [DOI] [PubMed] [Google Scholar]
  28. Weber M. A., Brewer D. D., Drayer J. I., Aronow W. S., Lipson J. L., Ricci B. A. A vasodilator that avoids renin stimulation and fluid retention: antihypertensive treatment with trimazosin. Clin Pharmacol Ther. 1982 May;31(5):572–578. doi: 10.1038/clpt.1982.80. [DOI] [PubMed] [Google Scholar]
  29. Woolhouse N. M., Andoh B., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians. Clin Pharmacol Ther. 1979 Nov;26(5):584–591. doi: 10.1002/cpt1979265584. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES